The 2026 Canadian Nephrology Trials Network Research Symposium at the Canadian Society of Nephrology AGM pre-course on Wednesday, May 6, is open for registration.
In-person attendees are welcome to join us at 7:30 AM ET for complimentary breakfast. The symposium will begin at 8:30 AM ET (virtual and in-person).
Please note that in-person registration is now full. Virtual attendance remains open, and we welcome you to join us online.
This hybrid event is your opportunity to:
-
Hear updates from ongoing and upcoming clinical trials in Canada
-
Learn what’s ahead for CNTN, and find out how you can get involved
-
Foster collaboration among researchers, trainees, and patient partners
View the full agenda and plain language summaries:
There will be presentations from:
- Kevin Yau – GUARD-1: Semaglutide in Dialysis Trial Insights: This study tests semaglutide in people on dialysis to see how safe and easy it is to use. Researchers will also look at Ontario health data to check for possible side effects of semaglutide and finerenone, such as low blood sugar, gallbladder issues, vision changes, or high potassium.
- Cal Robinson – KIDBP-Trials: Canadian Childhood Kidney Disease and Blood Pressure Trials Network: This initiative focuses on building a national clinical trials network for children with kidney disease and hypertension. The goal is to support research that addresses real-world challenges and improves care for children and families across Canada.
- Christine A. White/ Rachel Holden – DLITE: Hemodialysis Frequency and Living Well: Multicenter RCT to determine whether twice-weekly Hemodialysis (HD) compared to thrice-weekly HD, maintains Days Alive and Out of the Hospital (DAOH), which is an important patient-centered goal and outcome that approximates time spent at home.
- Sarah Melville (presenting on behalf of Martin G. MacKinnon and Jacob Michaud) – Hemodialysis Prescribing Patterns in New Brunswick: This observational study looks at how hemodialysis is currently prescribed across hospital and satellite centres in New Brunswick, and whether shorter or less frequent treatments may be a safe option for some patients. Findings suggest that reduced treatment time may help improve quality of life, particularly for older adults or those with palliative care goals.
Please note the CNTN Research Symposium is open to all, with virtual attendance available.
Questions? Contact CNTN Research Coordinator Omo Enilama at omo.enilama@phc.ca.